These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 28899974)
1. Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance. Nooij LS; Ter Haar NT; Ruano D; Rakislova N; van Wezel T; Smit VTHBM; Trimbos BJBMZ; Ordi J; van Poelgeest MIE; Bosse T Clin Cancer Res; 2017 Nov; 23(22):6781-6789. PubMed ID: 28899974 [No Abstract] [Full Text] [Related]
2. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy. Kashofer K; Regauer S Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674 [TBL] [Abstract][Full Text] [Related]
3. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Kortekaas KE; Bastiaannet E; van Doorn HC; de Vos van Steenwijk PJ; Ewing-Graham PC; Creutzberg CL; Akdeniz K; Nooij LS; van der Burg SH; Bosse T; van Poelgeest MIE Gynecol Oncol; 2020 Dec; 159(3):649-656. PubMed ID: 32972785 [TBL] [Abstract][Full Text] [Related]
4. Role of TP53 mutations in vulvar carcinomas. Choschzick M; Hantaredja W; Tennstedt P; Gieseking F; Wölber L; Simon R Int J Gynecol Pathol; 2011 Sep; 30(5):497-504. PubMed ID: 21804386 [TBL] [Abstract][Full Text] [Related]
5. Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. Weberpals JI; Lo B; Duciaume MM; Spaans JN; Clancy AA; Dimitroulakos J; Goss GD; Sekhon HS Clin Cancer Res; 2017 Aug; 23(15):4501-4510. PubMed ID: 28377483 [No Abstract] [Full Text] [Related]
6. Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. Flowers LC; Wistuba II; Scurry J; Muller CY; Ashfaq R; Miller DS; Minna JD; Gazdar AF J Soc Gynecol Investig; 1999; 6(4):213-21. PubMed ID: 10486784 [TBL] [Abstract][Full Text] [Related]
7. The Genomic Landscape of Vulvar Squamous Cell Carcinoma. Corey L; Wallbillich JJ; Wu S; Farrell A; Hodges K; Xiu J; Nabhan C; Guastella A; Kheil M; Gogoi R; Winer I; Bandyopadhyay S; Huang M; Jones N; Wilhite A; Karnezis A; Thaker P; Herzog TJ; Oberley M; Korn WM; Vezina A; Morris R; Ali-Fehmi R Int J Gynecol Pathol; 2023 Sep; 42(5):515-522. PubMed ID: 37131274 [TBL] [Abstract][Full Text] [Related]
8. The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer. Sznurkowski JJ; Żawrocki A; Biernat W BMC Cancer; 2016 Jul; 16():465. PubMed ID: 27411473 [TBL] [Abstract][Full Text] [Related]
9. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status. Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117 [TBL] [Abstract][Full Text] [Related]
10. Prognostication of vulvar cancer based on p14ARF status: molecular assessment of transcript and protein. Lavorato-Rocha AM; de Melo Maia B; Rodrigues IS; Stiepcich MM; Baiocchi G; da Silva Cestari FM; Carvalho KC; Soares FA; Rocha RM Ann Surg Oncol; 2013 Jan; 20(1):31-9. PubMed ID: 22878614 [TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature. Trietsch MD; Nooij LS; Gaarenstroom KN; van Poelgeest MI Gynecol Oncol; 2015 Jan; 136(1):143-57. PubMed ID: 25448458 [TBL] [Abstract][Full Text] [Related]
12. Carcinoma of the vulva: HPV and p53 mutations. Lee YY; Wilczynski SP; Chumakov A; Chih D; Koeffler HP Oncogene; 1994 Jun; 9(6):1655-9. PubMed ID: 8183560 [TBL] [Abstract][Full Text] [Related]
13. Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures. Zhang Y; Koneva LA; Virani S; Arthur AE; Virani A; Hall PB; Warden CD; Carey TE; Chepeha DB; Prince ME; McHugh JB; Wolf GT; Rozek LS; Sartor MA Clin Cancer Res; 2016 Sep; 22(18):4735-45. PubMed ID: 27091409 [TBL] [Abstract][Full Text] [Related]
14. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Trietsch MD; Spaans VM; ter Haar NT; Osse EM; Peters AA; Gaarenstroom KN; Fleuren GJ Gynecol Oncol; 2014 Oct; 135(1):149-55. PubMed ID: 25072932 [TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. McAlpine JN; Leung SCY; Cheng A; Miller D; Talhouk A; Gilks CB; Karnezis AN Histopathology; 2017 Aug; 71(2):238-246. PubMed ID: 28257152 [TBL] [Abstract][Full Text] [Related]
16. Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR). Dong F; Kojiro S; Borger DR; Growdon WB; Oliva E Am J Surg Pathol; 2015 Aug; 39(8):1045-53. PubMed ID: 26171917 [TBL] [Abstract][Full Text] [Related]